ArticleHemaSphere2026
Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis-endemic setting.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
In HIV- and tuberculosis (TB)-endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform-a plasma cell-free DNA (cfDNA)-based approach capturing molecular features of lymphoma and key pathogens. Plasma cfDNA undergoes ultra-low-pass whole genome sequencing and deep targeted sequencing (50,000× coverage). The combined output-including estimated tumor fraction, mutations, copy number alterations, structural variants, B- and T-cell receptor clonality, and pathogen detection-is integrated into a machine-learning classifier developed within this study to differentiate malignant from benign lymphadenopathy. In a prospective cohort of 124 South African patients with lymphadenopathy due to lymphoma (76.6%), benign causes (18.6%; TB adenitis [9.7%] and reactive [8.9%]), and disseminated solid tumors (4.8%), patients with lymphoma had higher cfDNA concentrations (mean 248.3 ng/mL), tumor fraction (mean 11.6%), and more mutations (mean 9.5), frequently in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.